WO1989000869A1 - Drainage du glaucome dans le systeme lacrimal - Google Patents
Drainage du glaucome dans le systeme lacrimal Download PDFInfo
- Publication number
- WO1989000869A1 WO1989000869A1 PCT/US1988/002694 US8802694W WO8900869A1 WO 1989000869 A1 WO1989000869 A1 WO 1989000869A1 US 8802694 W US8802694 W US 8802694W WO 8900869 A1 WO8900869 A1 WO 8900869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tube
- eye
- drainage system
- outlet end
- lacrimal
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 32
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 210000000795 conjunctiva Anatomy 0.000 claims description 7
- 210000003717 douglas' pouch Anatomy 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 abstract description 6
- 210000001742 aqueous humor Anatomy 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000004891 communication Methods 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 37
- 238000001356 surgical procedure Methods 0.000 description 9
- 210000003786 sclera Anatomy 0.000 description 5
- 208000002352 blister Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 240000008100 Brassica rapa Species 0.000 description 2
- 241001274216 Naso Species 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004083 nasolacrimal duct Anatomy 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000428533 Rhis Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
Definitions
- This invention relates to the field of ophthal ⁇ mology, and particularly to devices and methods for conducting fluids within and about the eye and the lacrimal drainage system.
- Glaucoma is a disease characterized by elevated intraocular pressure which, if not checked, may lead to nerve damage and visual loss. Pressures in the range of from about 15 + 3mm Hg up to about 21mm Hg may be considered to be in the normal range for human beings, whereas pressures substantially above that range are considered abnormally high. If pressures in the higher range are maintained for substantial periods of time, damage to the optic nerve of the eye may occur, leading to a narrowing of the field of vision and eventually to blindness if not appropri ⁇ ately treated.
- glaucoma can be treated through the administration of certain medi ⁇ cines such as pilocarpine, epinephrine and timolol maleate, it is often necessary to surgically provide - for the release of intraocular pressure for those patients who do not respond to drug therapy or who continue to lose vision under therapy.
- certain medi ⁇ cines such as pilocarpine, epinephrine and timolol maleate
- the exterior end of a tube extending through the wall of the eye is provided with a pressure relief valve in the form of small slits made through the wall of the tube at its end.
- a pressure relief valve in the form of small slits made through the wall of the tube at its end.
- N.T. Mascati describes a different method of drainage in "A New Surgical Approach for the Control of a Class of Glaucomas", International Surgery, Vol. 47:10-15 (1967). Dr. Mascati tried inserting one end of a drainage tube into the anterior chamber of an eye and the other end of the tube into the nasolacrimal duct. This procedure met with -only limited success, and is not currently employed due, presumably, to problems in ocular pressure control, infections and related complications.
- the Mascati device had no means for controlling liquid flow such as a pressure relief valve there was no way (1) to prevent collapse cf the anrericr chamber of the eye and (2) to prevent reflux of fluid from the naso ⁇ lacrimal drainage system into the anterior chamber of the eye during sneezing or nose-blowing.
- the invention provides a device and method for relieving high intraocular pressures associated with glaucoma.
- the device includes a flexible tube having one end extendable into the anterior chamber of the eye and having its other end in communication with the lacrimal drainage system of the eye.
- One-way valve means are provided within the tube to restrain liquid flow within the tube to a direction toward the lacri ⁇ mal drainage system. Since the lacrimal drainage system is lined with epithelial cells and is a natural passageway for fluid flow,, the scarring from fibrous tissue usually associated with draining is avoided.
- the one-way valve means also prevents back flow of fluids from the lacrimal drainage system into the eye, thus avoiding ascension of infection into the eye.
- One embodiment of the ocular device has filter means carried by the tube for restraining particles from passing therethrough toward the anterior chamber of the eye to further protect the eye from infection.
- the method comprises the steps of inserting the one end of the tube into the anterior chamber of the eye, allowing aqueous humor to escape into the tube, and attaching the other tube end to the eye so that fluid will drain into the lacrimal drainage system.
- the outlet end of the tube may be inserted into-the canaliculi, conjunctival cul-de-sac, lacrimal sac, lacrimal duct, lacrimal passage, or nasal passage te ⁇ allow fluid flow outwardly from the tube into the passages of the nasolacrimal system.
- Another embodiment: of the invention desirably employs a air of one-way valves wirhin the rube. Both one-way valves permit fluid flow only from the anterior chamber into the lacrimal drainage system.
- One one-way valve desirably is positioned at or near the tube end (inlet end) that will be placed into the anterior chamber.
- the other one-way valve desirably is positioned at or near the tube end (outlet end) inserted into the lacrimal drainage system.
- Figure 1 is a front view of an eye showing a nasolacrimal drainage system and the device of this invention
- Figure 2 is a cross-section of an eye showing a tube implanted by the method of this invention
- Figure 3 is a top view of a device of this invention.
- Figure 4 is a cross-sectional view along the line A-A of the device of Figure 3.
- Figure 1 shows somewhat schematically the front of a human eye and the lacrimal drainage system.
- the lacrimal gland (not shown) continuously supplies the eye with lacrimal fluid or tears.
- the lacrimal fluid washes across the conjunctiva (11) and the cornea (16).
- Excess lacrimal fluid not retained by the eye is commonly drained to the nasal passages, the infer ⁇ ior nasal meatus (not shown) in particular.
- the excess fluid is drained through a network of passages that commences with the puncta that appears as a small papilla adjacent the inner canthus or. the inner corner of the eye.
- the fluid is collected in the lacrimal sac (23) by a number of canaliculi (20) connecting the puncta to the sac.
- the sac (23) is then drained through its extension, the naso ⁇ lacrimal duct (24) which passes into the inferior nasal eatus for this purpose.
- This network of passages is referred to herein as the lacrimal drainage system (25).
- a tube (30) has an inlet end portion (31) that is shaped to be inserted through a small incision made in the wall of the eye so that the end (31) is posi ⁇ tioned in the interior of the eye, preferably in the anterior chamber.
- the other outlet end (32) of the tube is shaped to be inserted through a small incision made in a portion of the lacrimal drainage system to be positioned therein.
- the tube (30), desirably is on the order of about 1 to about 8cm long and about 0. to about 1.5 mm in outer diameter.
- the end portions may be of a comparatively rigid material such as poly- methylmethacrylate or of a metal such as gold or other biologically acceptable materials, and the ends may be joined together by a more flexible length of, e.g. , silicone rubber tubing.
- the entire length of the tube (30) r including the end portions is preferably made of a flexible material such as silicone or poly ⁇ ethylene.
- FIG 2 a cross-section of the human eye is shown that includes the device of the invention implanted in the anterior chamber.
- the cornea is shown as (16), the iris as (17), the lens as (18) and the limbus as (19).
- the inlet tube end (31) extends into the anterior chamber (14) of the eye and the outlet tube end (32) is positioned in the conjunc- tival cul-de-sac to allow fluid to flow from the tube ⁇ into the lacrimal drainage system.
- the device may be secured to the sclera (15) by sutures (34) or other conventional means.
- the one-way valve (35) or valves used with this invention may be of any of the various types suitable for use in the quite miniature device of the inven ⁇ tion, and such valves often also function as pressure relief valves as well.
- the one-way valve employed in this method desirably is competent to prevent back flow of fluid even against increases of pressure such as those that may occur within the lacrimal drainage system when a person sneezes, blows his nose or sneezes when the nose is plugged, e.g., 50 mm Hg.
- the one-way valve preferably is also a pressure relief valve that is adapted to open when the pressure in the eye exceeds the pressure within the tube by a pre-set threshold pressure, e.g. by about 8-lOmm Hg.
- the pressure within the tube will be maintained at or near atmospheric pressure (about 760mm Hg) .
- the valve prevents collapse of the anterior chamber.
- the unidirectional flow of the fluid into the lacrimal drainage system prevents viruses and bacteria carried by fluids in the lacrimal drainage system from being carried upwardly into the interior of the patient's eye through the tube.
- the valves may be any of a variety of well known designs which need not be described in detail, but which might include by way of example well known "duck valves".
- the one-way valve (35) may function as a pressure relief valve, the edges of the valve flaps pressing against one another to restrain fluid flow until the pressure differential across the valve increases to a level sufficient to cause the flaps to separate slightly, permitting fluid to pass. Reversal of the pressure gradient, as when the patient- sneezes, causes the flaps to press more tightly., together, thus restricting flow in the opposite direction.
- the valve When a tube having only one valve is used, the valve is positioned near the inlet end of the tube. The valve is thus more effective as a pressure relief valve, and back flow of fluid pooling within the tube is prevented.
- the outlet end of the tube is desirably surgi ⁇ cally inserted into the eye adjacent to or in the lacrimal drainage system.
- the tube end may be inserted in the conjunctival cul-de sac, the inferior or superior canaliculi (20), the lacrimal sac (23), the lacrimal duct (24), the nasal passage or any of the nasolacrimal passages or the nose. Fluid flows from the anterior chamber (14) of the eye through the tube (30) and into the passages of the lacrimal drainage system (25) and ultimately into the nasopharnyx where, if it has not been absorbed, it is swallowed.
- the ocular device shown in Figures 3 and 4 includes a microporous filter (40) that restrains micro-organisms and other particles having a mean diameter greater than the pore size from passing therethrough toward the anterior chamber of the eye.
- the filter may be of any known type such as a milli- pore filter made by the Millipore Company of Bedford, Mass.
- the filter desirably has a nominal pore size in the range of 0.1 micron to 10 microns and preferably has a pore size in the range of 0.1 ro 0.3 micron.
- the filter may be carried within rhe tube or it may be carried at the outlet end of the tube enclosing the end.
- the filter may be bag—shaped and extend outwardly of the tube end.
- the - bag-shaped filter may comprise a pair of filter -sheets (41,42) joined at their peripheries ro define an interior space (43) communicating wirh rhe outler end of the tube.
- a rather large limbal based flap of conjunctiva (11) is opened with an incision of about 6 to 10 mm posterior to the limbus. Care should be taken to provide no tears or button-holing of the conjunctiva. If tears occur, they should be repaired.
- the episcleral tissue (13) should be cleared from the region of the limbus (19) back for a distance (i.e., 5-8 mm) and any bleeding controlled with gentle cautery.
- the posterior margin of the conjunctiva (11) will be lifted and Tenon's capsule (12) interrupted with combined blunt and sharp dissection until the bare sclera of the eye is visible.
- a partial thickness scleral flap is outlined, the flap desirably measuring 4-5 mm in width and approximately 4-6 mm in anterior- posterior length.
- the tube (30) should be positioned under the scleral flap and a small incision made into the anterior chamber (14) at the limbus (19). The tube end (31) will then be threaded into the anterior chamber (14) until it can be visualized through the clear cornea (16).
- the limbal incision may be closed about the tube (30) and if a flange (33) is attached to the tube, it may be secured to the bed of the sclera (15) with partial thickness scleral bites and through-and- through bites through the flange (33) with a suture.
- a false channel may be created surgically in the posterior lateral wall of the sac.
- the tube end (32) is then threaded through that channel into the sac (23) and if desired, into the nasolacrimal duct (24).
- the length of the tube (30) must be sufficient to permit slippage of the tube within the sac when the eyeball rotates without dislodging the tube.
- outlet end of the tube (32) is to be inserted into the canaliculi (20) it will desirably be threaded through the backside of the eyelid and then into the posterior wall of the canaliculus.
- the out ⁇ let end of the tube (32) may be attached to the eye so that it is positioned in the conjunctival cul-de-sac adjacent the lacrimal drainage system.
- outlet tube end (32) is inserted into the nasolacrimal system (25), it is fixed to the sur ⁇ face of the sclera (15) under the conjunctiva (11) in the episcleral space.
- the tube (30) may be fixed to the eye using any well known surgical method such as sutures or scleral tunnels (34).
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Prostheses (AREA)
Abstract
Dispositif et procédé permettant à du fluide de s'écouler à partir de l'intérieur de l'oeil jusque dans le système (25) de drainage nasolacrimal associée à l'oeil, afin de soulager la pression intra-oculaire élevée dans le traitement du glaucome. Le procédé utilise un tube (30) souple doté d'une extrémité extensible à l'intérieur de la chambre (16) antérieure de l'oeil, et dont l'autre extrémité est en communication avec le système (25) de drainage nasolacrimal de l'oeil. Une valve (35) unidirectionnelle est prévue à l'intérieur du tube afin de limiter l'écoulement de liquide dans une direction allant de la chambre (16) antérieure de l'oeil vers le système (25) de drainage lacrimal. Le procédé comprend les étapes consistant à introduire une extrémité (31) du tube dans la chambre (16) antérieure de l'oeil et à introduire l'autre extrémité du tube dans une partie du système (25) de drainage nasolacrimal. On laisse s'échapper de l'humeur aqueuse dans le tube, à l'extrémité (31) de la chambre antérieure, laquelle s'écoule vers l'extérieur dans les passages du système nasolacrimal (25). Une ou plusieurs valves (35) unidirectionnelles situées à l'intérieur du tube ne permettent l'écoulement du fluide qu'à l'opposé de la chambre antérieure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US082,837 | 1979-10-09 | ||
US8283787A | 1987-08-06 | 1987-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989000869A1 true WO1989000869A1 (fr) | 1989-02-09 |
Family
ID=22173766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/002694 WO1989000869A1 (fr) | 1987-08-06 | 1988-08-08 | Drainage du glaucome dans le systeme lacrimal |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2308988A (fr) |
CA (1) | CA1295907C (fr) |
WO (1) | WO1989000869A1 (fr) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078631A3 (fr) * | 2000-04-14 | 2002-04-18 | Glaukos Corp | Appareil et procede de traitement du glaucome |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
WO2004060219A1 (fr) * | 2002-12-27 | 2004-07-22 | Japan Science And Technology Agency | Implant de drainage d'humeur aqueuse pour le traitement du glaucome |
US7094225B2 (en) | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
US7135009B2 (en) | 2001-04-07 | 2006-11-14 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7811268B2 (en) | 2005-02-21 | 2010-10-12 | Artom S.A. | Device for draining aqueous humor in cases of glaucoma |
US7879001B2 (en) | 2002-04-08 | 2011-02-01 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8771217B2 (en) | 1999-04-26 | 2014-07-08 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9220632B2 (en) | 2002-03-07 | 2015-12-29 | Glaukos Corporation | Fluid infusion methods for ocular disorder treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
CN111449834A (zh) * | 2020-04-15 | 2020-07-28 | 贵州省人民医院 | 一种泪小管栓塞用泪道引流装置及其引流方法 |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
-
1988
- 1988-08-08 AU AU23089/88A patent/AU2308988A/en not_active Abandoned
- 1988-08-08 WO PCT/US1988/002694 patent/WO1989000869A1/fr unknown
- 1988-08-08 CA CA000574099A patent/CA1295907C/fr not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
Non-Patent Citations (1)
Title |
---|
INTERNATIONAL SURGERY, Vol. 47, No. 1, January 1967, NAUMANN T. MASCATI, "A New Surgical Approach for the Control of a Class of Glaucomas", (Note pages 10-15). * |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771217B2 (en) | 1999-04-26 | 2014-07-08 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
EP2260804B2 (fr) † | 1999-04-26 | 2022-03-02 | Glaukos Corporation | Dispositif pour trabéculotomie de traitement du glaucome |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
EP2260804B1 (fr) | 1999-04-26 | 2016-10-19 | Glaukos Corporation | Dispositif pour trabéculotomie de traitement du glaucome |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9789001B2 (en) | 2000-04-14 | 2017-10-17 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US9066782B2 (en) | 2000-04-14 | 2015-06-30 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8814820B2 (en) | 2000-04-14 | 2014-08-26 | Glaukos Corporation | Ocular implant with therapeutic agent and methods thereof |
WO2001078631A3 (fr) * | 2000-04-14 | 2002-04-18 | Glaukos Corp | Appareil et procede de traitement du glaucome |
US6736791B1 (en) | 2000-04-14 | 2004-05-18 | Glaukos Corporation | Glaucoma treatment device |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9155654B2 (en) | 2001-04-07 | 2015-10-13 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US8075511B2 (en) | 2001-04-07 | 2011-12-13 | Glaukos Corporation | System for treating ocular disorders and methods thereof |
US8062244B2 (en) | 2001-04-07 | 2011-11-22 | Glaukos Corporation | Self-trephining implant and methods thereof for treatment of ocular disorders |
US8579846B2 (en) | 2001-04-07 | 2013-11-12 | Glaukos Corporation | Ocular implant systems |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US7135009B2 (en) | 2001-04-07 | 2006-11-14 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US7857782B2 (en) | 2001-04-07 | 2010-12-28 | Glaukos Corporation | Ocular implant delivery system and method thereof |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US7273475B2 (en) | 2001-05-03 | 2007-09-25 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US7094225B2 (en) | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
US8337445B2 (en) | 2001-05-03 | 2012-12-25 | Glaukos Corporation | Ocular implant with double anchor mechanism |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US7879079B2 (en) | 2001-08-28 | 2011-02-01 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9561131B2 (en) | 2001-08-28 | 2017-02-07 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9220632B2 (en) | 2002-03-07 | 2015-12-29 | Glaukos Corporation | Fluid infusion methods for ocular disorder treatment |
US8882781B2 (en) | 2002-03-15 | 2014-11-11 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US7879001B2 (en) | 2002-04-08 | 2011-02-01 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US9597230B2 (en) | 2002-04-08 | 2017-03-21 | Glaukos Corporation | Devices and methods for glaucoma treatment |
WO2004060219A1 (fr) * | 2002-12-27 | 2004-07-22 | Japan Science And Technology Agency | Implant de drainage d'humeur aqueuse pour le traitement du glaucome |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US9844462B2 (en) | 2003-05-05 | 2017-12-19 | Novartis Ag | Internal shunt and method for treating glaucoma |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US10226380B2 (en) | 2003-11-14 | 2019-03-12 | Novartis Ag | Ocular pressure regulation |
US7811268B2 (en) | 2005-02-21 | 2010-10-12 | Artom S.A. | Device for draining aqueous humor in cases of glaucoma |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US9789000B2 (en) | 2006-01-17 | 2017-10-17 | Novartis Ag | Glaucoma treatment device |
US10905590B2 (en) | 2006-01-17 | 2021-02-02 | Alcon Inc. | Glaucoma treatment device |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9421130B2 (en) | 2006-01-17 | 2016-08-23 | Novartis Ag. | Glaucoma treatment device |
US11786402B2 (en) | 2006-01-17 | 2023-10-17 | Alcon Inc. | Glaucoma treatment device |
US9668917B2 (en) | 2006-01-17 | 2017-06-06 | Novartis Ag | Drug delivery treatment device |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US10531983B2 (en) | 2009-01-28 | 2020-01-14 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US11344448B2 (en) | 2009-01-28 | 2022-05-31 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US11839571B2 (en) | 2009-01-28 | 2023-12-12 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9907697B2 (en) | 2012-04-24 | 2018-03-06 | Novartis Ag | Delivery system for ocular implant |
US10912676B2 (en) | 2012-04-24 | 2021-02-09 | Alcon Inc. | Delivery system for ocular implant |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US10849558B2 (en) | 2013-03-13 | 2020-12-01 | Glaukos Corporation | Intraocular physiological sensor |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11992551B2 (en) | 2014-05-29 | 2024-05-28 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
CN111449834B (zh) * | 2020-04-15 | 2022-03-01 | 贵州省人民医院 | 一种泪小管栓塞用泪道引流装置及其引流方法 |
CN111449834A (zh) * | 2020-04-15 | 2020-07-28 | 贵州省人民医院 | 一种泪小管栓塞用泪道引流装置及其引流方法 |
Also Published As
Publication number | Publication date |
---|---|
CA1295907C (fr) | 1992-02-18 |
AU2308988A (en) | 1989-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4886488A (en) | Glaucoma drainage the lacrimal system and method | |
CA1295907C (fr) | Drainage du glaucome dans le systeme lacrimal | |
US10485702B2 (en) | System and method for treating an ocular disorder | |
EP0532654B1 (fr) | Implant oculaire pour le traitement des glaucomes | |
US4729761A (en) | Tissue-implantable, fluid-dissipating device | |
EP0228185B1 (fr) | Dispositif implantable dans les tissus humains pour disperser des liquides | |
US5397300A (en) | Glaucoma implant | |
AU2001245698B2 (en) | Device for glaucoma treatment and methods thereof | |
US5433701A (en) | Apparatus for reducing ocular pressure | |
US20030236483A1 (en) | Dual drainage ocular shunt for glaucoma | |
EP2521517B1 (fr) | Dispositif ophtalmique chirurgical | |
AU2001245698A1 (en) | Device for glaucoma treatment and methods thereof | |
JP2002541976A (ja) | 緑内障を治療するためのステント装置および方法 | |
WO2002036052A1 (fr) | Dispositif de traitement du glaucome | |
JP2017519592A (ja) | 緑内障の眼圧制御のための排水装置 | |
WO1993020783A1 (fr) | Implant pour le traitement du glaucome | |
WO2007006466A1 (fr) | Dispositif destine au traitement d'un glaucome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |